Please use this identifier to cite or link to this item:
|Title:||Systemic therapies for pancreatic cancer - the role of pharmacogenetics|
|Authors:||Soo, R.A. |
|Source:||Soo, R.A.,Yong, W.-P.,Innocenti, F. (2012-06). Systemic therapies for pancreatic cancer - the role of pharmacogenetics. Current Drug Targets 13 (6) : 811-828. ScholarBank@NUS Repository. https://doi.org/10.2174/138945012800564068|
|Abstract:||Effective systemic treatment of pancreatic cancer remains a major challenge, with progress hampered by drug resistance and treatment related toxicities. Currently available cytotoxic agents as monotherapy or in combination have provided only a modest survival benefit for patients with advanced disease. Disappointing phase III results with gemcitabine-based combinations in patients with advanced pancreatic cancer might be related to poor efficacy of systemic therapies in unselected patients. Future research strategies should prioritize identification of predictive markers through pharmacogenetic investigations. The individualization of patient treatment through pharmacogenetics may help to improve outcome by maximizing efficacy whilst lowering toxicity. This review provides an update on the pharmacogenetics of pancreatic cancer treatment and its influence on treatment benefits and toxicity. © 2012 Bentham Science Publishers.|
|Source Title:||Current Drug Targets|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Feb 20, 2018
checked on Feb 22, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.